We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10).